Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company that describes itself as committed to delivering a new class of differentiated one-time curative genetic therapies using its proprietary Prime Editing platform. The PRME news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how this Prime Editing strategy progresses from research to clinical data and corporate milestones.
According to its public announcements, Prime Medicine is advancing a diversified portfolio of investigational programs focused on liver, lung, and immunology and oncology. News items highlight specific programs such as PM577 for H1069Q-driven Wilson’s Disease, PM647 for Alpha-1 Antitrypsin Deficiency, an in vivo Cystic Fibrosis program supported by the Cystic Fibrosis Foundation, and PM359 for p47phox chronic granulomatous disease. Updates may include preclinical data presentations, first-in-human clinical data, and information about how Prime Editing is being applied across these indications.
Investors and observers can also use the PRME news page to follow corporate developments disclosed by the company, such as participation in healthcare and genetic medicines conferences, leadership appointments, financing transactions, and strategic collaborations, including efforts with Bristol Myers Squibb on Prime Edited CAR-T products. Because Prime Medicine regularly issues press releases in connection with quarterly financial results, pipeline updates, and investor events, the news stream offers a way to track changes in its pipeline priorities, regulatory plans, and capital markets activity over time.
By reviewing the PRME news feed, users can see how Prime Medicine communicates progress on its Prime Editing platform, key disease programs, and business strategy. Bookmarking this page provides a single location to review recent announcements, clinical and preclinical data disclosures, and other material updates that the company has chosen to release publicly.
Prime Medicine (Nasdaq: PRME) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. FDA clearance for PM359, a Prime Editor for chronic granulomatous disease (CGD), to enter clinical trials.
2. Promotion of Dr. Mohammed Asmal to Chief Medical Officer.
3. Advancing multiple programs across core focus areas.
4. R&D expenses increased to $43.1 million from $34.6 million in Q2 2023.
5. Net loss widened to $55.3 million from $42.4 million in Q2 2023.
6. Cash position of $176.4 million as of June 30, 2024.
The company anticipates initial clinical data for PM359 in 2025 and plans to advance several programs in hematology, immunology, liver, ocular, and neuromuscular areas.
Prime Medicine, a biotechnology firm traded on Nasdaq under the symbol PRME, announced that CEO Keith Gottesdiener will present at two upcoming investor conferences. The first presentation will be at the Jefferies Healthcare Conference on June 5, 2024, at 1:30 p.m. ET in New York, NY. The second presentation will be at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 2:00 p.m. ET in Miami Beach, FL. Live audio webcasts of both events will be available in the 'Events & Presentations' section on the company's website, with replays accessible for 90 days post-event.
Prime Medicine, Inc. (Nasdaq: PRME) will have Allan Reine, M.D., Chief Financial Officer, participating in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024.
The company is focused on delivering innovative one-time curative genetic therapies, with the event allowing investors to gain insights into Prime Medicine's future endeavors.
Prime Medicine, Inc. (Nasdaq: PRME) reported financial results for Q1 2024, highlighting FDA clearance of its first-ever IND application for PM359 for CGD treatment. They also presented new preclinical data demonstrating Prime Editing technology's potential and appointed Tony Coles, M.D., as a senior advisor. The company is focused on advancing its pipeline programs and strengthening its Prime Editing platform.
Prime Medicine, Inc. presents preclinical data showing PM359's ability to correct CGD mutation, with FDA clearance for Phase 1/2 trial. CGD is a rare disease causing severe infections. PM359 demonstrated high correction rates, restored neutrophil function, and clinical-scale production of edited cells.
Prime Medicine, Inc. (Nasdaq: PRME) will participate in the 27th Annual Milken Institute Global Conference with its CEO, Dr. Keith Gottesdiener, discussing cutting-edge technologies and scientific breakthroughs. The panel aims to offer insights into the future and will be livestreamed on May 8, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Prime Medicine (PRME)?
What is the market cap of Prime Medicine (PRME)?
